Showing 2161-2170 of 3315 results for "".
- Major League Soccer All-Star Alecko Eskandarian to Speak at Annual NORA Conferencehttps://modernod.com/news/major-league-soccer-all-star-alecko-eskandarian-to-speak-at-annual-nora-conference/2476364/Two-time Major League Soccer (MLS) All-Star Alecko Eskandarian will be the key-note speaker at the Neuro-Optometric Rehabilitation Association, International (NORA) 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona.
- New Data From Alcon Shows that Compliant Contact Lens Wear Can Improve Practice Outcomeshttps://modernod.com/news/new-data-from-alcon-shows-that-compliant-contact-lens-wear-can-improve-practice-outcomes/2479590/Alcon unveiled new data from its Power of One 2.0 Program showing how patient compliance with daily and monthly contact lens replacement schedules can significantly improve patient and practice outcomes. The Power of One Program is a contact lens strategy centered on 1-day and 1-month contact len
- Allergan Responds to Public Shareholder Letterhttps://modernod.com/news/allergan-responds-to-public-shareholder-letter/2476274/Allergan issued the following statement from its Board of Directors in response to a public shareholder letter from Appaloosa hedge fund manager David Tepper earlier this week that stated the drugmaker should consider a merger or selling itself if it is “unable or unwilling to hold manageme
- Bausch + Lomb Acquires Eton Pharmaceuticals’ EM-100 Investigational OTC Eye Drop For Allergic Conjunctivitishttps://modernod.com/news/bausch-health-acquires-eton-pharmaceuticals-em-100-investigational-eye-drop-for-the-treatment-of-itchy-eyes-associated-with-allergies/2476282/Bausch Health Companies’ subsidiary Bausch + Lomb has acquired the US rights to Eton Pharmaceuticals’ investigational eye drop EM-100. If approved, the eye drop will be the first over-the-counter preservative-free formulation eye drop for the treatment of ocular itching associated wit
- VSY Biotechnology and Carl Zeiss Meditec Settle Legal Disputeshttps://modernod.com/news/vsy-biotechnology-and-carl-zeiss-meditec-settle-legal-disputes/2476289/VSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced that both companies resolved their legal and patent disputes with respect to the Tri-ED 611 IOL. The companies did not disclose the terms of the settlement.
- Leiters and Mobius Therapeutics Enter into National Sales and Marketing Agreement for Mitosolhttps://modernod.com/news/leiters-and-mobius-therapeutics-enter-into-national-sales-and-marketing-agreement-for-mitosol/2476290/Leiters and Mobius Therapeutics announced that they have entered into a national sales and marketing agreement for Mitosol, the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Leiters, an FDA-registered 503B outsourcing provider
- Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible Hydra-PEG Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-receives-510k-clearance-for-use-of-the-tangible-hydra-peg-custom-contact-lens-coating-on-several-lenses/2476297/Bausch + Lomb announced it has received 510(k) clearance for use of the Tangible Hydra-PEG custom contact lens coating technology with some of its leading Boston gas permeable (GP) materials, the Boston XO, Boston XO2, Boston EO, and Boston ES lenses, including th
- Pr3vent Completes Series A Financing Led By InFocus Capital Partnershttps://modernod.com/news/pr3vent-completes-series-a-financing-led-by-infocus-capital-partners/2476301/Pr3vent, a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners. The announcement comes on the heels of a successful seed round in October 2018 led by the joint investment of Skyview Ventures and Tro
- Our Artificial Cornea Breakthrough Could Lead to Self-Assembling Organshttps://modernod.com/news/our-artificial-cornea-breakthrough-could-lead-to-self-assembling-organs/2476305/For every person in the world who receives a cornea transplant, there are 69 others who still need one. That leaves about 12.5m people with limited sight because there aren’t enough eye donors. But what if we cou
- GenSight’s Gene Therapy GS010 Fails Second Late-Stage Leber Hereditary Optic Neuropathy Studyhttps://modernod.com/news/gensights-gene-therapy-gs010-fails-second-late-stage-leber-hereditary-optic-neuropathy-study/2476321/GenSight Biologics announced that a phase 3 study investigating a single injection of the experimental gene therapy GS010 failed to improve vision loss compared to sham treatment in patients with 11778-ND4 Leber hereditary optic neuropathy (LHON). In the RESCUE study, patients with